SCHEMBL4903045

SCHEMBL4903045

CCN(Oc1cc(Cl)cc(Cl)c1)S(=O)(=O)c1ccc(C)c(C(=O)OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
TSHR P16473 4/20 0.53
EPAS1 Q99814 1/20 0.40
CYP2C9 P11712 3/20 0.40
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899746 0.89 LMNA (0.42) ALDH1A1TSHRCYP2C9CRHBPCRHR2
SCHEMBL4902618 0.83 ALDH1A1 (0.46) ALDH1A1TSHRCYP2C9SMN1; SMN2MEN1
SCHEMBL4906721 0.83 ALDH1A1 (0.46) ALDH1A1TSHRCYP2C9SMN1; SMN2MEN1
SCHEMBL4909548 0.79 MMP9 (0.48) ALDH1A1TSHRSMN1; SMN2MEN1NPC1
SCHEMBL4907398 0.79 ALDH1A1 (0.42) ALDH1A1TSHRSMN1; SMN2KMT2AMAPT
SCHEMBL4905146 0.78 ALDH1A1 (0.50) ALDH1A1TSHRSMN1; SMN2MAPTTP53
SCHEMBL4900658 0.76 ALDH1A1 (0.55) ALDH1A1TSHRCYP2C9SMN1; SMN2MEN1
SCHEMBL4895843 0.75 ALDH1A1 (0.50) ALDH1A1TSHRSMN1; SMN2KMT2AMAPT
SCHEMBL4899484 0.75 ALDH1A1 (0.39) ALDH1A1TSHRCYP2C9SMN1; SMN2MEN1
SCHEMBL4899320 0.75 ALDH1A1 (0.52) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
EP-1765796-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Inc. (US) 2007-03-28 EP disclosed
WO-2006003495-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2006-01-12 WO disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD ALDH1A1 2956/4885TSHR 400/4885EPAS1 100/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD ALDH1A1 2956/4885TSHR 400/4885EPAS1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.